Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Home
Authors
Posts by Tess Egginton
Tess Egginton
1400 POSTS
0 COMMENTS
http://www.pbiforum.net
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
13th February 2025
BridgeBio’s BEYONTTRA approved by European Commission to treat ATTR-CM
13th February 2025
UK unveils funding for AI companies to transform cancer care and...
13th February 2025
U.S. FDA approves SpringWorks Therapeutics’ GOMEKLI for patients with NF1-PN
12th February 2025
U.S. FDA approves EMBLAVEO for adults with complicated intra-abdominal infections
12th February 2025
Bain Capital to acquire Mitsubishi Tanabe Pharma Corporation
11th February 2025
Novartis bolsters late-stage cardiovascular pipeline with acquisition of Anthos Therapeutics
11th February 2025
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15,...
11th February 2025
FDA orphan drug and rare pediatric disease designations granted to Arbor...
11th February 2025
1
2
3
...
140
Page 1 of 140
News
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, have announced a collaboration and...
Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData
14th February 2025
The Duchenne muscular dystrophy (DMD) market across the seven major markets (7MM*) is set to grow from $2.3 billion in 2023 to $5.2 billion...
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
13th February 2025
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a...